A novel IgG-Fc-Fused multiepitope vaccine against Brucella: robust immunogenicity.

IF 4.3 2区生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Microbial Cell Factories Pub Date : 2025-04-15 DOI:10.1186/s12934-025-02713-0

Aodi Wu, Yuting Zhang, Caidong Liu, Kaiat Zhumanov, Tao He, Kexin Yan, Honghuan Li, Shuangshaung Fu, Xin Li, Wenxiang Zhang, Chuang Meng, Changsuo Zhang, Jinliang Sheng, Zhongchen Ma, Mingguo Xu, Junbo Zhang, Jihai Yi, Yueli Wang

{"title":"A novel IgG-Fc-Fused multiepitope vaccine against Brucella: robust immunogenicity.","authors":"Aodi Wu, Yuting Zhang, Caidong Liu, Kaiat Zhumanov, Tao He, Kexin Yan, Honghuan Li, Shuangshaung Fu, Xin Li, Wenxiang Zhang, Chuang Meng, Changsuo Zhang, Jinliang Sheng, Zhongchen Ma, Mingguo Xu, Junbo Zhang, Jihai Yi, Yueli Wang","doi":"10.1186/s12934-025-02713-0","DOIUrl":null,"url":null,"abstract":"<p><p>Brucellosis is one of the most common zoonotic diseases caused by Brucella spp. However, there is currently no Brucella vaccine available for humans. Although some attenuated live vaccines have been approved for animals, their protective efficacy is suboptimal. In previous studies, we utilized an epitope- and structure-based vaccinology platform to identify the immunodominant epitopes of Brucella antigens OMP19, OMP16, OMP25, and L7/L12, and constructed the multi-epitope vaccine MEV-Fc against Brucella. In this study, OMP19, OMP16, OMP25, and L7/L12, and MEV-Fc was expressed and purified via an Escherichia coli expression system, which validated that MEV-Fc possesses high immunological efficacy and exerts a significant protective effect in BALB/c mice within the Brucella infection model. MEV-Fc enhanced Th1 and Th2 immune responses and strongly induced the production of the pro-inflammatory cytokine IFN-γ. Furthermore, MEV-Fc protected mice against Brucella infection compared to control group (PBS). In conclusion, our results provide new insights and data support for the development of human Brucella vaccines.</p>","PeriodicalId":18582,"journal":{"name":"Microbial Cell Factories","volume":"24 1","pages":"84"},"PeriodicalIF":4.3000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998165/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial Cell Factories","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s12934-025-02713-0","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Brucellosis is one of the most common zoonotic diseases caused by Brucella spp. However, there is currently no Brucella vaccine available for humans. Although some attenuated live vaccines have been approved for animals, their protective efficacy is suboptimal. In previous studies, we utilized an epitope- and structure-based vaccinology platform to identify the immunodominant epitopes of Brucella antigens OMP19, OMP16, OMP25, and L7/L12, and constructed the multi-epitope vaccine MEV-Fc against Brucella. In this study, OMP19, OMP16, OMP25, and L7/L12, and MEV-Fc was expressed and purified via an Escherichia coli expression system, which validated that MEV-Fc possesses high immunological efficacy and exerts a significant protective effect in BALB/c mice within the Brucella infection model. MEV-Fc enhanced Th1 and Th2 immune responses and strongly induced the production of the pro-inflammatory cytokine IFN-γ. Furthermore, MEV-Fc protected mice against Brucella infection compared to control group (PBS). In conclusion, our results provide new insights and data support for the development of human Brucella vaccines.

查看原文本刊更多论文

一种新型的igg - fc融合多表位布鲁氏菌疫苗：强大的免疫原性。

布鲁氏菌病是由布鲁氏菌引起的最常见的人畜共患疾病之一，然而，目前还没有可用于人类的布鲁氏菌疫苗。虽然一些减毒活疫苗已被批准用于动物，但其保护效果并不理想。在前期研究中，我们利用基于表位和结构的疫苗学平台，鉴定了布鲁氏菌抗原OMP19、OMP16、OMP25和L7/L12的免疫优势表位，构建了布鲁氏菌多表位疫苗MEV-Fc。本研究通过大肠杆菌表达系统对OMP19、OMP16、OMP25、L7/L12和MEV-Fc进行了表达和纯化，验证了MEV-Fc具有较高的免疫功效，对布鲁氏菌感染模型内BALB/c小鼠具有显著的保护作用。MEV-Fc增强Th1和Th2免疫应答，并强烈诱导促炎细胞因子IFN-γ的产生。此外，与对照组（PBS）相比，MEV-Fc可以保护小鼠免受布鲁氏菌感染。总之，我们的研究结果为人类布鲁氏菌疫苗的开发提供了新的见解和数据支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Microbial Cell Factories 工程技术-生物工程与应用微生物

CiteScore

9.30

自引率

4.70%

发文量

235

审稿时长

2.3 months

期刊介绍： Microbial Cell Factories is an open access peer-reviewed journal that covers any topic related to the development, use and investigation of microbial cells as producers of recombinant proteins and natural products, or as catalyzers of biological transformations of industrial interest. Microbial Cell Factories is the world leading, primary research journal fully focusing on Applied Microbiology. The journal is divided into the following editorial sections: -Metabolic engineering -Synthetic biology -Whole-cell biocatalysis -Microbial regulations -Recombinant protein production/bioprocessing -Production of natural compounds -Systems biology of cell factories -Microbial production processes -Cell-free systems